Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...

The Federal Circuit has vacated a District of Delaware ruling in a patent case which found that patent claims asserted by ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

The new drug, Bristol Myers Squibb’s Cobenfy ... and a team sorted through more than 7,000 combinations before hitting on ...

The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.

and prescription medications. By addressing both the physical and emotional aspects of OAB, people with overactive bladder can learn to gain control of a condition that affects up to 33% of ...

These "fixes" include lifestyle modifications, pelvic floor exercises, fluid management, and the appropriate use of over-the-counter (OTC) and prescription medications. By addressing both the physical ...

There are many new treatment options for the overactive bladder that are discussed in this article, including the recently introduced drugs tolterodine and oxybutynin XL. Other drugs are in ...

PARIS – New, more expensive migraine drugs are no more effective against the throbbing headaches than traditional painkillers and even performed worse than an older range of treatments called ...